Taiwan Liposome Company: TLC is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine proprietary lipid-assembled drug delivery platforms with approved active pharmaceutical ingredients (APIs). TLC's extensive experience with liposome science allows fast onset speed, prolonged benefit duration, and improved API concentrations at target tissues while decreasing unwanted systemic exposures. Product candidates span across pain (TLC599 for osteoarthritis pain (Ph2 complete, Ph3 1H2019), TLC590 for postsurgical pain (Ph1/2)), ophthalmology (TLC399 for macular edema (Ph2)), and oncology (TLC178 for rhabdomyosarcoma (Ph1/2)). All programs expected to be in late or pivotal stage by the end of 2020.
2F, 3 Yuanqu Street, Nangang District
Taipei , 11503

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.